1. A pharmaceutical composition comprising a pharmaceutically acceptable carrier and a purified monoclonal antibody which specifically binds *Staphylococcus aureus* protein A (SpA) with a K_D of less than 1 x 10^{-10} M via its Fab region paratope, wherein the monoclonal antibody is able to mediate opsinization of SpA-expressing *Staphylococcus aureus* bacteria in the presence of at least 1 mg/ml of IgG immunoglobulins which bind SpA via their Fc regions.

2. The pharmaceutical composition of claim 1, wherein the monoclonal antibody is a human or humanized IgG3 monoclonal antibody.

3. The pharmaceutical composition of claim 1, wherein the monoclonal antibody specifically binds to the amino acid sequence: KPGKEDNKKPGKEDGNKPGK (SEQ ID NO: 1).

4. The pharmaceutical composition of claim 2, wherein the monoclonal antibody comprises:

(i) a heavy chain comprising a CDR1, CDR2, and CDR3 of SEQ ID NO: 2, 3, and 4, respectively, and a light chain comprising a CDR1, CDR2, and CDR3 of SEQ ID NO: 7, 8, and 9, respectively;

(ii) a heavy chain comprising a CDR1, CDR2, and CDR3 of SEQ ID NO: 12, 13, and 14, respectively, and a light chain comprising a CDR1, CDR2, and CDR3 of SEQ ID NO: 17, 18, and 19, respectively;

(iii) a heavy chain comprising a CDR1, CDR2, and CDR3 of SEQ ID NO: 22, 23, and 24, respectively, and a light chain comprising a CDR1, CDR2, and CDR3 of SEQ ID NO: 27, 28, and 29, respectively;

(iv) a heavy chain comprising a CDR1, CDR2, and CDR3 of SEQ ID NO: 32, 33, and 34, respectively, and a light chain comprising a CDR1, CDR2, and CDR3 of SEQ ID NO: 37, 38, and 39, respectively;

(v) a heavy chain comprising a CDR1, CDR2, and CDR3 of SEQ ID NO: 42, 43, and 44, respectively, and a light chain comprising a CDR1, CDR2, and CDR3 of SEQ ID NO: 47, 48, and 49, respectively;

(vi) a heavy chain comprising a CDR1, CDR2, and CDR3 of SEQ ID NO: 52, 53, and 54, respectively, and a light chain comprising a CDR1, CDR2, and CDR3 of SEQ ID NO: 57, 58, and 59, respectively;

(vii) a heavy chain comprising a CDR1, CDR2, and CDR3 of SEQ ID NO: 62, 63, and 64, respectively, and a light chain comprising a CDR1, CDR2, and CDR3 of SEQ ID NO: 67, 68, and 69, respectively; or

(viii) a heavy chain comprising a CDR1, CDR2, and CDR3 of SEQ ID NO: 72, 73, and 74, respectively, and a light chain comprising a CDR1, CDR2, and CDR3 of SEQ ID NO: 77, 78, and 79, respectively.

5. The pharmaceutical composition of claim 2, wherein the monocloanl antibody comprises a heavy chain variable domain comprising SEQ ID NO: 5 and a light chain variable domain comprising SEQ ID NO: 10.

6. A pharmaceutical composition comprising a pharmaceutically acceptable carrier and a purified monoclonal antibody which specifically binds Staphylococcus aureus protein A (SpA) with a K_D of less than 1 x 10^{-10} M via its Fab region, wherein the monoclonal antibody is able to displace human IgG immunoglobulins bound to SpA on *Staphylococcusaureus* bacteria via their Fc regions.

7. The pharmaceutical composition of claim 6, wherein the antibody has a set of six CDRs that has no more than one, two, three, or four total amino acid substitutions in the set of six CDRs selected from the group consisting of:

(i) SEQ ID NOs: 2, 3, 4, 7, 8, and 9;

(ii) SEQ ID NOs: 12, 13, 14, 17, 18, and 19;

(iii) SEQ ID NOs: 22, 23, 24, 27, 28, and 29;

(iv) SEQ ID NOs: 32, 33, 34, 37, 38, and 39;

(v) SEQ ID NOs: 42, 43, 44, 47, 48, and 49;

(vi) SEQ ID NOs: 52, 53, 54, 57, 58, and 59;

(vii) SEQ ID NOs: 62, 63, 64, 67, 68, and 69; and

(viii) SEQ ID NOs: 72, 73, 74, 77, 78, and 79.

8. The pharmaceutical composition of claim 7, wherein the antibody has no more than two total amino acid substitutions in the set of six CDRs.

9. The pharmaceutical composition of claim 7, wherein the antibody antibody has no amino acid substitutions in the set of six CDRs

10. The pharmaceutical composition of claim 7, wherein the antibody comprises a set of six CDRs of SEQ ID NOs: 2, 3, 4, 7, 8, and 9.

11. A pharmaceutically acceptable carrier and a human or humanized IgG3 monoclonal antibody that specifically binds to a SpA epitope, wherein the antibody comprises a variable domain selected from the group of:

(i) SEQ ID NO: 5;
(ii) SEQ ID NO: 10;
(iii) SEQ ID NO: 15;
(iv) SEQ ID NO: 20;
(v) SEQ ID NO: 25;
(vi) SEQ ID NO: 30;
(vii) SEQ ID NO: 35;
(viii) SEQ ID NO: 40;
(ix) SEQ ID NO: 45;
(x) SEQ ID NO: 50;
(xi) SEQ ID NO: 55;
(xii) SEQ ID NO: 60;
(xiii) SEQ ID NO: 65;
(xiv) SEQ ID NO: 70;
(xv) SEQ ID NO: 75; or
(xvi) SEQ ID NO: 80.

12. The pharmaceutical composition of claim 1, wherein the monoclonal antibody binds SpA with a K_D of less than 1 x 10^{-12} M via its Fab region.

1. A pharmaceutical composition comprising a pharmaceutically acceptable carrier and a purified monoclonal antibody comprising a heavy chain variable domain comprising a CDR1, CDR2, and CDR3 of SEQ ID NO: 2, 3, and 4, respectively, and a light chain variable domain comprising a CDR1, CDR2, and CDR3 of SEQ ID NO: 7, 8, and 9, respectively, wherein the monoclonal antibody specifically binds *Staphylococcus aureus* protein A (SpA) with a K_D of less than 1×10^{-10} M its Fab region paratope, wherein the monoclonal antibody is able to displace human IgG immunoglobulins bound to SpA on *Staphylococcus aureus* bacteria via their Fc regions.

2. The pharmaceutical composition of claim 1, wherein the monoclonal antibody is able to mediate opsonization of SpA-expressing *Staphylococcus aureus* bacteria in the presence of at least 1 mg/ml of IgG immunoglobulins which bind SpA via their Fc regions.

3. The pharmaceutical composition of claim 1, wherein the monoclonal antibody is a human or humanized IgG3 monoclonal antibody.

4. The pharmaceutical composition of claim 1, wherein the monoclonal antibody specifically binds to the amino acid sequence SEQ ID NO: 1.

5. The pharmaceutical composition of claim 1, wherein the heavy chain variable domain comprises SEQ ID NO: 5 and the light chain variable domain comprises SEQ ID NO: 10.

6. The pharmaceutical composition of claim 5, wherein the monoclonal antibody is able to mediate opsonization of SpA-expressing *Staphylococcus aureus* bacteria in the presence of at least 1 mg/ml of IgG immunoglobulins which bind SpA via their Fc regions.

7. The pharmaceutical composition of claim 5, wherein the monoclonal antibody is a human or humanized IgG3 monoclonal antibody.

8. The pharmaceutical composition of claim 5, wherein the monoclonal antibody specifically binds to the amino acid sequence SEQ ID NO: 1.